[1] MARINA N, GEBHARDT M, TEOT L, et al. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9(4):422-441.
[2] PICCI P, Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2007;2:6.
[3] HEARE T, HENSLEY MA, DELL’ORFANO S. Bone tumors: osteosarcoma and Ewing’s sarcoma. Curr Opin Pediatr. 2009;21(3):365-372.
[4] GUILLON MA, MARY PM, BRUGIERE L, et al. Clinical characteristics and prognosis of osteosarcoma in young children: a retrospective series of 15 cases. BMC Cancer. 2011;11:407.
[5] MISAGHI A, GOLDIN A, AWAD M, et al. Osteosarcoma: a comprehensive review. SICOT J. 2018;4:12.
[6] LOH AH, NAVID F, WANG C, et al. Management of local recurrence of pediatric osteosarcoma following limb-sparing surgery. Ann Surg Oncol. 2014;21(6):1948-1955.
[7] EBB D, MEYERS P, GRIER H, et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology group. J Clin Oncol. 2012;30(20):2545-2551.
[8] AU KM, SATTERLEE A, MIN Y, et al. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: turning a bone antiresorptive agent into an anticancer therapeutic. Biomaterials. 2016;82:178-193.
[9] WACHTEL M and SCHAFER BW, Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev. 2010;36(4):318-327.
[10] WU JJ, WILLIAMS GR, ZHU Y, et al. Ultrathin chalcogenide nanosheets for photoacoustic imaging-guided synergistic photothermal/gas therapy. Biomaterials. 2021;273:120807.
[11] WANG J, HU X, XIANG D. Nanoparticle drug delivery systems: an excellent carrier for tumor peptide vaccines. Drug Deliv. 2018;25(1):1319-1327.
[12] CHEN C, XIE L, REN T, et al. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1-10.
[13] LIU Y, NADEEM A, SEBASTIAN S, et al. Bone mineral: a trojan horse for bone cancers. efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin. Materials today Bio. 2022;14: 100227.
[14] HE T, YUAN YY, JIANG C, et al. Light-triggered transformable ferrous ion delivery system for photothermal primed chemodynamic therapy. Angew Chem Int Edit. 2021;60(11): 6047-6054.
[15] CHU BY, QU Y, HE XL, et al. ROS-responsive camptothecin prodrug nanoparticles for on-demand drug release and combination of chemotherapy and photodynamic therapy. Adv Funct Mater. 2020;30(52): 2005918.
[16] DONG SJ, CHEN Y, YU LD, et al. Magnetic hyperthermia-synergistic H2O2 self-sufficient catalytic suppression of osteosarcoma with enhanced bone-regeneration bioactivity by 3D-printing composite scaffolds. Adv Funct Mater. 2020;30(4):1907071.
[17] BERHE S, DANZER E, MEYERS P, et al. Unusual abdominal metastases in osteosarcoma. J Pediatr Surg Case Rep. 2018;28:13-16.
[18] RAINUSSO N, WANG LL, YUSTEIN JT. The adolescent and young adult with cancer: state of the art - bone tumors. Curr Oncol Rep. 2013;15(4):296-307.
[19] 孙郁文,魏鹏,陈启旺,等.阿霉素结合骨修复材料应用于骨肉瘤治疗的研究进展[J].实用骨科杂志,2019,25(8):728-733.
[20] OGAWA Y, UE H, TSUZUKI K, et al. New radiosensitization treatment (KORTUC I) using hydrogen peroxide solution-soaked gauze bolus for unresectable and superficially exposed neoplasms. Oncol Rep. 2008;19(6):1389-1394.
[21] BLATTMANN C, OERTEL S, THIEMANN M, et al. Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy. Radiat. Oncol. 2015;10:146.
[22] 李耀明,姜宏,石永芳.壳聚糖/聚乳酸/羟基磷灰石/聚乙烯醇复合材料骨支架的制备及表征[J].中国组织工程研究,2022,26(18):2888-2893.
[23] CHEN ZW, ZHANG PD, XU Y, et al. Surgical stress and cancer progression: the twisted tango. Mol Cancer. 2019;18(1):132.
[24] HARRISON DJ, GELLER DS, GILL JD, et al. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39-50.
[25] XU M, XU F, YU C. Clinical analysis of osteosarcoma patients treated with high-dose methotrexate-free neoadjuvant chemotherapy. Curr Oncol. 2014; 21(5):E678-E684.
[26] ANDO K, HEYMANN MF, STRESING V, et al. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers. 2013;5(2):591-616.
[27] TCHOUNWOU PB, DASARI S, NOUBISSI FK, et al. Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. J Exp Pharmacol. 2021;13:303-328.
[28] WITTIG JC, BICKELS J, PRIEBAT D, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002;65(6): 1123-1132.
[29] CHEN B, YANG JZ, WANG LF, et al. Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma. BMC Cancer. 2015;15:752.
[30] WANG YC, DAI HL, LI ZH, et al. Mesoporous polydopamine-coated hydroxyapatite nano-composites for ROS-triggered nitric oxide-enhanced photothermal therapy of osteosarcoma. J Mat Chem B. 2021;9(36): 7401-7408.
[31] ISAKOFF MS, BIELACK SS, MELTZER P, et al. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029-3127.
[32] WYCISLO KL, FAN TM. The Immunotherapy of canine osteosarcoma: a historical and systematic review. J Vet Intern Med. 2015;29(3):759-769.
[33] HUANG R, WANG MW, ZHU YZ, et al. Development of PET probes for cancer imaging. Curr Top Med Chem. 2015;15(8):795-819.
[34] JIN YY, NI DL, GAO L, et al. Harness the power of upconversion nanoparticles for spectral computed tomography diagnosis of osteosarcoma. Adv Funct Mater. 2018;28(33):1802656.
[35] JOKERST JV, GAMBHIR SS. Molecular imaging with theranostic nanoparticles. Accounts Chem Res. 2011;44(10):1050-1060.
[36] YANG R, KOLB EA, QIN J, et al. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res. 2007; 13(9):2557-2567.
[37] CIPRESTE MF, PERES AM, COTTA AAC, et al. Synthesis and characterization of Gd-159-doped hydroxyapatite nanorods for bioapplications as theranostic systems. Mater Chem Phys. 2016;181:301-311.
[38] LU Y, LI LH, LIN ZF, et al. Enhancing Osteosarcoma Killing and CT imaging using ultrahigh drug loading and NIR-responsive bismuth sulfide@mesoporous silica nanoparticles. Adv Healthc Mater. 2018;7(19):1800602.
[39] IMANI R, DILLERT R, BAHNEMANN DW, et al. Multifunctional gadolinium-doped mesoporous TiO2 nanobeads: photoluminescence, enhanced spin relaxation, and reactive oxygen species photogeneration, beneficial for cancer diagnosis and treatment. SMALL. 2017;13(20):1700349.
[40] KOPP LM, WOMER RB, SCHWARTZ CL, et al. Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group. Cardiooncology. 2019;5(1):15.
[41] CHAMBERLAIN FE, JONES RL, CHAWLA SP. Aldoxorubicin in soft tissue sarcomas. Future Oncol. 2019;15(13):1429-1435.
[42] WANG SD, LI B, ZHANG HL, et al. Improving bioavailability of hydrophobic prodrugs through supramolecular nanocarriers based on recombinant proteins for osteosarcoma treatment. Angew Chem Int Edit. 2021;60(20):11252-11256.
[43] GHOSH S, RAJU RSK, GHOSH N, et al. Development and physicochemical characterization of doxorubicin-encapsulated hydroxyapatite-polyvinyl alcohol nanocomposite for repair of osteosarcoma-affected bone tissues. C R Chim. 2019;22(1):46-57.
[44] LIU YJ, QIAO ZG, GAO J, et al. Hydroxyapatite-bovine serum albumin-paclitaxel nanoparticles for locoregional treatment of osteosarcoma. Adv Healthc Mater. 2021;10(2):2000573.
[45] TAN BW, WU YT, WU YZ, et al. Curcumin-microsphere/IR820 hybrid bifunctional hydrogels for in situ osteosarcoma chemo-co-thermal therapy and bone reconstruction. ACS Appl Mater Interfaces. 2021;13(27):31542-31553.
[46] YOKOI K, KOJIC M, MILOSEVIC M, et al. Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. Cancer Res. 2014;74(16):4239-4246.
[47] CHENG YH, HE CL, RIVIERE JE, et al. Meta-analysis of nanoparticle delivery to tumors using a physiologically based pharmacokinetic modeling and simulation approach. ACS Nano. 2020;14(3):3075-3095.
[48] MICHIELS C, TELLIER C, FERON O. Cycling hypoxia: a key feature of the tumor microenvironment. Biochim Biophys Acta. 2016;1866(1):76-86.
[49] MAEDA H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliver Rev. 2015;91:3-6.
[50] ZHOU HY, HERNANDEZ C, GOSS M, et al. Biomedical imaging in implantable drug delivery systems. Curr. Drug Targets. 2015;16(6):672-682.
[51] MENG E, HOANG T, Micro- and nano-fabricated implantable drug-delivery systems. Ther Deliv. 2012;3(12):1457-1467.
[52] WANG YH, SUN L, MEI ZG, et al. 3D printed biodegradable implants as an individualized drug delivery system for local chemotherapy of osteosarcoma. Mater Des. 2020;186:108336.
[53] LIU Y, RAINA DB, SEBASTIAN S, et al. Sustained and controlled delivery of doxorubicin from an in-situ setting biphasic hydroxyapatite carrier for local treatment of a highly proliferative human osteosarcoma. Acta Biomater. 2021;131:555-571.
[54] YOON SJ, MOON YJ, CHUN HJ, et al. Doxorubicin center dot hydrochloride/cisplatin-loaded hydrogel/nanosized (2-hydroxypropyl)-beta-cyclodextrin local drug-delivery system for osteosarcoma treatment in vivo. Nanomaterials. 2019;9(12):1652.
[55] WU Y, WOODBINE L, CARR AM, et al. 3D printed calcium phosphate cement (CPC) scaffolds for anti-cancer drug delivery. Pharmaceutics. 2020;12(11):1077.
[56] 吕奇,洪嵩.恶性骨肿瘤切除后用于骨缺损修复的生物材料的研究进展[J].生物骨科材料与临床研究,2022,19(1):75-79.
[57] WILHELM S, TAVARES AJ, DAI Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014.
[58] MATSUMURA Y, MAEDA H. A new concept for macromolecular therapeutics in cancer-chemotherapy - mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12):6387-6392.
[59] FANG J, NAKAMURA H, MAEDA H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136-151.
[60] LAMMERS T, KIESSLING F, HENNINK WE, et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012; 161(2):175-187.
[61] NICHOLS JW, BAE YH. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today. 2012;7(6):606-618.
[62] GILLIES RJ, SCHORNACK PA, SECOMB TW, et al. Causes and effects of heterogeneous perfusion in tumors. Neoplasia (New York). 1999;1(3):197-207.
[63] NICHOLS JW, BAE YH. EPR: Evidence and fallacy. J Control Release. 2014;190:451-464.
[64] FLYNN T, WEI CM. The pathway to commercialization for nanomedicine. Nanomed Nanotechnol Biol Med. 2005;1(1):47-51.
[65] WANG SY, HU HZ, QING XC, et al. Recent advances of drug delivery nanocarriers in osteosarcoma treatment. J Cancer. 2020;11(1):69-82.
[66] XU SF, LU HZ, ZHENG XW, et al. Stimuli-responsive molecularly imprinted polymers: versatile functional materials. J Mater Chem C. 2013;1(29): 4406-4422.
[67] PENG HL, DONG RC, WANG SQ, et al. A pH-responsive nano-carrier with mesoporous silica nanoparticles cores and poly(acrylic acid) shell-layers: fabrication, characterization and properties for controlled release of salidroside. Int J Pharm. 2013;446(1-2):153-159.
[68] SENAPATI S, MAHANTA AK, KUMAR S, et al. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018;3:7.
[69] WANG CF, MA ZJ, YUAN KM, et al. Using scaffolds as drug delivery systems to treat bone tumor. Nanotechnology. 2022;33(21):212002. |